What are the diagnostic criteria for Alzheimer’s disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Diagnostic Criteria for Alzheimer's Disease

Alzheimer's disease should be diagnosed using a clinical-biological approach that requires both specific clinical phenotypes AND positive biomarkers (amyloid-β and tau), with the diagnosis restricted to symptomatic individuals rather than applying to all biomarker-positive persons 1, 2.

Core Diagnostic Framework

The most recent guidelines emphasize a two-pronged approach:

1. Clinical Criteria for Probable AD Dementia

The patient must first meet general dementia criteria, then demonstrate 2:

Temporal Pattern:

  • Insidious onset over months to years (not sudden)
  • Clear-cut history of progressive cognitive worsening

Cognitive Presentations (one must be prominent):

  • Amnestic (most common): Impaired learning and recall of recent information, plus dysfunction in at least one other cognitive domain
  • Language: Prominent word-finding deficits with other domain impairments
  • Visuospatial: Deficits in spatial cognition (object agnosia, face recognition, simultanagnosia, alexia) with other domain involvement
  • Executive: Impaired reasoning, judgment, and problem-solving with other domain deficits

Exclusion Criteria - Do NOT diagnose probable AD dementia if 2:

  • Substantial cerebrovascular disease (stroke temporally related to cognitive decline, multiple infarcts, severe white matter disease)
  • Core features of dementia with Lewy bodies
  • Prominent behavioral variant frontotemporal dementia features
  • Prominent primary progressive aphasia features
  • Other active neurological disease or medications substantially affecting cognition

2. Biomarker Requirements

The International Working Group strongly recommends against diagnosing AD based on biomarkers alone 1. Instead:

  • Core 1 biomarkers (amyloid PET, CSF biomarkers, or plasma phosphorylated tau-217) establish the biological diagnosis 3
  • Biomarker-positive but cognitively normal individuals should be classified as "at-risk for AD," NOT as having AD 1
  • When both amyloid-β and tau/neurodegeneration biomarkers are positive in symptomatic patients, likelihood of AD is high 2

Mild Cognitive Impairment (MCI) Due to AD

Diagnose MCI when 2:

  1. Cognitive concern reported by patient, informant, or clinician
  2. Objective impairment in one or more cognitive domains (typically memory)
  3. Preserved independence in functional abilities (key differentiator from dementia)
  4. Does not meet dementia criteria

Likelihood MCI is due to AD:

  • High: Both amyloid-β AND neurodegeneration biomarkers positive
  • Intermediate: One biomarker positive, other untested or conflicting results
  • Low: Both biomarkers negative

Critical Diagnostic Workflow

Step 1: Structured history covering cognition, daily function, mood/behavior, and sensorimotor function from both patient and reliable informant 2

Step 2: Mental status examination assessing cognition, mood, and behavior using validated tools 2

Step 3: Dementia-focused neurologic examination 2

Step 4: MRI recommended for all patients with recent cognitive decline 4

Step 5: Biomarker testing (amyloid PET, CSF, or validated plasma biomarkers) when diagnosis impacts treatment decisions 3, 4

Important Caveats

The 2025 Alzheimer's Association guidelines explicitly state they do NOT recommend biomarker testing in asymptomatic individuals because no approved interventions exist for preclinical AD 2. This directly contradicts purely biological definitions that would diagnose AD in cognitively normal people with positive biomarkers 1.

Common pitfall: The shift toward biological definitions has created confusion. The most recent specialty care guidelines 2 maintain that clinical syndrome plus biomarkers is the appropriate diagnostic standard, rejecting the 2018 NIA-AA framework that defined AD by biomarkers alone 1. This represents a critical evolution recognizing that biomarker positivity without symptoms represents risk, not disease 1.

Blood-based biomarkers (especially p-tau217) are promising but validation for routine clinical use is still evolving 4. They should currently be used to guide decisions about more definitive CSF or PET testing rather than as standalone diagnostic tools.

The probabilistic relationship between clinical syndrome and pathology means multiple etiologies are common, especially in patients over 85 years 2. Biomarkers increase diagnostic confidence but do not eliminate clinical judgment about competing or co-existing pathologies.

References

3
Research

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024

Related Questions

What is the appropriate diagnostic workup for suspected Alzheimer’s disease in an older adult presenting with progressive memory loss and cognitive changes?
What evidence links Alzheimer's dementia to a genetic predisposition?
In an 80-year-old patient with Alzheimer disease experiencing sundowning, what medication regimen can be used to manage the symptoms?
Is there a test for Alzheimer’s disease for an individual with a family history of dementia?
In an elderly patient with Alzheimer’s disease who is sleeping 12–14 hours per day and has poor oral intake, why is a positron emission tomography (PET) scan preferred over a computed tomography (CT) scan for assessing dementia severity and progression?
What is the recommended naloxone regimen to reverse fentanyl overdose in an adult?
Does tadalafil affect the contractile function of cardiac muscle?
What is the likely diagnosis and recommended treatment for tiny skin-colored itchy papules in the axillae?
How should I reverse a warfarin‑induced International Normalized Ratio (INR) greater than 9 in a patient presenting with hemoptysis?
What patient education should be included in a SOAP note for a person with type 1 diabetes mellitus?
How is brain tissue oxygen tension (PbtO2) measured in an adult severe traumatic brain injury patient who is intubated and mechanically ventilated in the ICU?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.